|
1. Biologie
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
AI used to detect breast cancer risk [BBC News]
|
|
|
|
|
|
The
machine learning system has been tested on 335 high-risk lesions, and
correctly diagnosed 97% as malignant. It reduced the number of
unnecessary surgeries by more than 30%, the scientists said.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
Personalised treatments for rare cancers tested in study [Cancer Research UK]
|
|
|
|
|
|
In
the latest trial, researchers studied 40 patients at the Rare Tumour
Clinic at the UC San Diego Moores Cancer Center with various rare
cancers, including sarcomas and cancers that could not be classified.
They used blood and tissue samples to analyse the tumours’ molecular and
genetic features, looking for those which could be targeted with drugs.
| |
|
|
|
5.12.7 Immunothérapies - vaccins
|
|
|
|
5.13 WCLC
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Responses to the comments from EMA [BMJ]
|
|
|
|
|
|
The
major point of Davis and colleagues is that while it may be ok to allow
cancer drugs on the market based on a surrogate, it seems illogical to
allow them to remain on the market 3, 5, or 7 years without proof of
survival or quality of life benefit. At some point in the lifecycle of
these drugs, this must be shown. The EMA has the obligation to make that
happen. These comments raises concern that the EMA views their role
differently.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.6 Publications
|
|
|
|
6.9 Controverses
|
|
|
|